Description

3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-7-[4-[3-(2-Fluorophenoxy)-1-Oxopropyl]-1-Piperazinyl]-1,4-Dihydro-4-Oxo- is a high-purity, advanced pharmaceutical intermediate critical for the synthesis of novel fluoroquinolone antibiotics. Its complex molecular structure, featuring a quinoline core with a piperazinyl side chain, is engineered to impart potent antibacterial activity and improved pharmacokinetic profiles. This compound is essential for research and development laboratories and manufacturing facilities focused on next-generation anti-infective agents, offering a reliable building block for creating more effective therapeutic solutions.

Application

• Key Intermediate for Fluoroquinolone Antibiotics: Serves as a crucial precursor in the multi-step synthesis of advanced, broad-spectrum antibacterial agents.
• Pharmaceutical R&D: Used in medicinal chemistry programs for the design, optimization, and structure-activity relationship (SAR) studies of new anti-infective drug candidates.
• Active Pharmaceutical Ingredient (API) Manufacturing: Employed in the scaled-up production of final drug substances under current Good Manufacturing Practice (cGMP) conditions.
• Process Chemistry Development: Utilized for developing and optimizing robust, cost-effective synthetic routes for new antibiotic molecules.
• Reference Standard: Acts as a high-purity analytical standard for quality control and regulatory submissions in drug development pipelines.

Basic Information

Product Name	3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-7-[4-[3-(2-Fluorophenoxy)-1-Oxopropyl]-1-Piperazinyl]-1,4-Dihydro-4-Oxo-
CAS No.	1053951-18-0
Molecular Formula	C26H25F2N3O4
Molecular Weight	481.49 g/mol
Synonyms	1-Cyclopropyl-6-fluoro-7-[4-[3-(2-fluorophenoxy)propanoyl]piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; WCK 771 Intermediate; Levonadifloxacin Intermediate; (S)-(-)-9-Fluoro-6,7-dihydro-8-(4-hydroxy-1-piperazinyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic Acid L-Alanine Salt (related); Benzo[i,j]quinolizine-2-carboxylic acid derivative; Anti-MRSA fluoroquinolone intermediate; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid derivative.
EINECS	Contact for details

Quality Control

Our 3-Quinolinecarboxylic Acid derivative is manufactured under strict quality systems to ensure batch-to-batch consistency and high purity, suitable for pharmaceutical applications. Quality is verified through a comprehensive suite of analytical techniques including HPLC, NMR, and Mass Spectrometry. A detailed Certificate of Analysis (COA) is provided with each batch, documenting purity, identity, and impurity profiles. We support development and commercial projects with materials that can meet the stringent requirements of ICH guidelines and regulatory submissions.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (typically 15-25°C). The product is light-sensitive and should be handled under appropriate conditions to maintain stability. Keep the container tightly sealed when not in use to protect from moisture.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C
Loss on Drying	≤ 0.5%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.